NEW DELHI – Artificial intelligence (AI) is increasingly gaining a foothold in India's health care landscape, with investors pouring money into the new technology, companies developing products and regulators looking to come up with much-needed rules.
NEW DELHI – Artificial intelligence (AI) is increasingly gaining a foothold in India's health care landscape, with investors pouring money into the new technology, companies developing products and regulators looking to come up with much-needed rules. India's Ministry of Health has reached out to the public for consultation on its national digital health blueprint that seeks to propel digital health care, including the use of AI in the biotech and medical technology sectors.
NEW DELHI – Artificial intelligence (AI) is increasingly gaining a foothold in India's health care landscape, with investors pouring money into the new technology, companies developing products and regulators looking to come up with much-needed rules.
HYDERABAD, India – India has modified its rules to allow the government to waive clinical trials for some new drugs that are approved and marketed in countries specified by India's apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO).
HYDERABAD, India – India has modified its rules to allow the government to waive clinical trials for some new drugs that are approved and marketed in countries specified by India's apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO).
HYDERABAD, India – As China surges ahead in the biosimilars space, Indian biopharma companies are increasingly concerned about their ability to keep pace due to lack of policy support and pricing controls.
HYDERABAD, India – Indian pharma companies have started taking baby steps toward using data analytics and artificial intelligence in drug discovery and development, joining a global trend of pharma companies embracing digital and cloud technologies. But those efforts are still ad-hoc and experimental.
HYDERABAD, India – Indian pharma companies have started taking baby steps toward using data analytics and artificial intelligence in drug discovery and development, joining a global trend of pharma companies embracing digital and cloud technologies. But those efforts are still ad-hoc and experimental.
